이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Corvus Pharmaceuticals 미래 성장

Future 기준 확인 0/6

Corvus Pharmaceuticals 의 수익은 연간 12.8% 감소할 것으로 예상되는 반면, 연간 수익은 71% 로 증가할 것으로 예상됩니다. 71% 연간. EPS는 연간 5.1% 만큼 성장할 것으로 예상됩니다.

주요 정보

-12.8%

수익 성장률

5.1%

EPS 성장률

Biotechs 수익 성장	24.1%
매출 성장률	71.0%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	09 May 2024

최근 미래 성장 업데이트

Recent updates

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

수익 및 매출 성장 예측

NasdaqGM:CRVS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	7	-56	-47	N/A	4
12/31/2025	N/A	-46	-30	N/A	4
12/31/2024	N/A	-30	-23	N/A	4
3/31/2024	N/A	-25	-21	-21	N/A
12/31/2023	N/A	-27	-24	-24	N/A
9/30/2023	N/A	-30	-26	-26	N/A
6/30/2023	N/A	-39	-28	-28	N/A
3/31/2023	N/A	-41	-29	-29	N/A
12/31/2022	N/A	-41	-27	-27	N/A
9/30/2022	N/A	-41	-27	-26	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-40	-34	-34	N/A
12/31/2021	N/A	-43	-37	-37	N/A
9/30/2021	N/A	-7	-38	-38	N/A
6/30/2021	N/A	-6	-37	-37	N/A
3/31/2021	N/A	-5	-34	-34	N/A
12/31/2020	N/A	-6	-35	-35	N/A
9/30/2020	N/A	-44	-35	-35	N/A
6/30/2020	N/A	-46	-38	-38	N/A
3/31/2020	N/A	-48	-38	-38	N/A
12/31/2019	N/A	-47	-37	-37	N/A
9/30/2019	N/A	-46	-37	-37	N/A
6/30/2019	N/A	-46	-38	-37	N/A
3/31/2019	N/A	-44	-39	-39	N/A
12/31/2018	N/A	-47	-41	-41	N/A
9/30/2018	N/A	-48	-44	-44	N/A
6/30/2018	N/A	-51	-44	-44	N/A
3/31/2018	N/A	-54	-45	-45	N/A
12/31/2017	N/A	-56	N/A	-46	N/A
9/30/2017	N/A	-55	N/A	-45	N/A
6/30/2017	N/A	-52	N/A	-41	N/A
3/31/2017	N/A	-46	N/A	-35	N/A
12/31/2016	N/A	-36	N/A	-28	N/A
9/30/2016	N/A	-31	N/A	-22	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-36	N/A	-15	N/A
12/31/2015	N/A	-31	N/A	-11	N/A
9/30/2015	N/A	-25	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CRVS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CRVS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CRVS 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CRVS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: CRVS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CRVS 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Corvus Pharmaceuticals 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 9.1% to US$7.50

Price target decreased to US$2.50

Price target increased to US$6.38

Price target increased to US$6.30

Price target increased to US$7.38

Price target decreased to US$6.50

Recent updates

Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million.

Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Price target increased by 9.1% to US$7.50

Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

New minor risk - Market cap size

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

New major risk - Revenue and earnings growth

Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors

Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

New major risk - Financial position

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

New minor risk - Market cap size

Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Price target decreased to US$2.50

Insufficient new directors

Corvus Pharmaceuticals, Inc. to Present Updated CPI-818 (ITK Inhibitor) Data At the American Society of Hematology Annual Meeting & Exposition

Corvus Pharmaceuticals Receives Written Notice from the Staff of the Listing Qualifications Department of Nasdaq

Corvus Pharmaceuticals, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Corvus Pharmaceuticals, Inc. Provides Business and Clinical Update

Corvus Pharmaceuticals, Inc. Appoints Dr. James Rosenbaum as Senior Vice President of Research

Price target increased to US$6.38

Insufficient new directors

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Chief Financial Officer recently bought US$77k worth of stock

Corvus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Insufficient new directors

Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as A Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Price target increased to US$6.30

Corvus Pharmaceuticals Provides Updates on Mupadolimab

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Independent Director Steve Krognes has left the company

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

Price target increased to US$7.38

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

Co-Founder recently bought US$100k worth of stock

Price target decreased to US$6.50

Co-Founder recently bought US$350k worth of stock

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

New 90-day high: US$4.28

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

New 90-day low: US$3.77

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals, Inc. Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Corvus Pharmaceuticals EPS misses by $0.06

Corvus Pharmaceuticals, Inc. Announces Updated Data from Its Ongoing Phase 1 Study Investigating the Potential for CPI-006

Corvus Pharmaceuticals, Inc. Announces New Data from its Clinical Collaboration with Genentech

Corvus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020